ライフサイエンスコーパス: macrolide

1 ry diverse ARGs (multidrug, acriflavine, and macrolide).

2 nd absolute configuration of this oxopolyene macrolide.

3 posite end of selvamicin's shortened polyene macrolide.

4 s in penicillin-allergic patients instead of macrolides.

5 one scaffold of MTM is smaller than in other macrolides.

6 amoxicillin-clavulanate, cephalosporins, and macrolides.

7 parately for penicillins, cephalosporins and macrolides.

8 ndard of care or to standard of care without macrolides.

9 Macrolides 1 and 2 inhibit mitochondrial function simila

10 1.365, 1.218-1.531), and chloroquine with a macrolide (22.2%; 1.368, 1.273-1.469) were each independ

11 % CI 1.223-1.457), hydroxychloroquine with a macrolide (23.8%; 1.447, 1.368-1.531), chloroquine (16.4

12 hloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 re

13 3.561, 2.760-4.596), and chloroquine with a macrolide (6.5%; 4.011, 3.344-4.812) were independently

14 369, 1.935-2.900), hydroxychloroquine with a macrolide (8.1%; 5.106, 4.106-5.983), chloroquine (4.3%;

15 ls (2), cephalosporins (7), penicillins (8), macrolides (8), benzimidazoles (20), coccidiostats (14),

16 al synthesis of the potent anti-trypanosomal macrolide (+)-actinoallolide A has been achieved in 17 s

17 ding polyketides, glycopeptides, terpenoids, macrolides, alkaloids, carbohydrates, and others.

18 gents that inhibit protein synthesis such as macrolides, along with fluoroquinolones that inhibit DNA

19 A formal total synthesis of the cytotoxic macrolide amphidinolide E is reported.

20 entifying the subspecies and determining the macrolide and aminoglycoside resistance levels of 50 Myc

21 This is a review of the macrolide and ketolide field focusing on differentiating

22 in MDA may result in a sustained increase in macrolide and other antibiotic resistance in gut and res

23 Rising macrolide and quinolone resistance in Mycoplasma genital

24 disease is dual-antimicrobial therapy with a macrolide and rifampin.

25 ress in this area, including our own work in macrolide and spirocyclic molecule synthesis.

26 ycin and cotrimoxazole led to an increase in macrolide and sulfonamide resistance determinants.

27 he presence of possible mutations leading to macrolide and tetracycline resistance.

28 e of this study was to examine the effect of macrolide and/or rifampin resistance on intracellular re

29 2011 to 1.49 in 2016, driven by decreases in macrolides and fluoroquinolones.

30 third- and fourth-generation cephalosporins, macrolides and ketolides, and glycopeptides.

31 sity in pharmacodynamics and toxicity of the macrolides and ketolides, resulting from even small stru

32 ynamics and especially the toxicology of the macrolides and ketolides.

33 exhibited high-level susceptibility to most macrolides and quinolones, and moderate susceptibility t

34 Concurrently with the increased use of macrolides and rifampin for chemoprophylaxis and the tre

35 and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group

36 nt antibiotic classes dominating in biomass (macrolides) and effluent (sulfonamides).

37 oroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these trea

38 , and antibiotics derived from beta-lactams, macrolides, and aminocoumarins.

39 roquinolone, third-generation cephalosporin, macrolides, and carbapenem use, exceeding hospital popul

40 tracyclines, sulfonamides, fluoroquinolones, macrolides, and coccidiostats) were monitored after cook

41 markers to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in 1102 resistant and s

42 class: terpenes, alkaloids, prostaglandins, macrolides, and tetracyclines.

43 current large-scale use of fluoroquinolones, macrolides, and third-generation cephalosporins and any

44 ealed that everninomicin P occupies both the macrolide- and orthosomycin-binding sites on the 70S rib

45 istinamycin was highly effective in treating macrolide- and quinolone-resistant strains.

46 , a significant increase in the incidence of macrolide- and rifampin-resistant R. equi isolates has b

47 in bacterial numbers over time and the dual macrolide- and rifampin-resistant strain exhibited decre

48 The widely used macrolide antibiotic azithromycin increases risk of card

49 We show that the macrolide antibiotic azithromycin reduced viral prolifer

50 Rationale: The macrolide antibiotic azithromycin reduces exacerbations

51 More than 300 new macrolide antibiotic candidates, as well as the clinical

52 ing reports regarding the association of the macrolide antibiotic clarithromycin with cardiovascular

53 Macrolide antibiotic rapamycin, in complex with a cytoso

54 onas vaginalis Sequencing was used to assess macrolide antibiotic resistance among M. genitalium-posi

55 lly transmitted organisms, and high rates of macrolide antibiotic resistance in a diverse sample of s

56 transmitted organisms and the frequency of a macrolide antibiotic resistance phenotype were determine

57 reactionary sites which are complementary to macrolide antibiotic spiramycin (SPI) were synthetized b

58 Treatment depends on macrolide antibiotic therapy and intubation, with assist

59 Here we demonstrate that a single pulsed macrolide antibiotic treatment (PAT) course early in lif

60 proved latrine (0.89; 0.82-0.97), and recent macrolide antibiotic use (0.68; 0.63-0.74).

61 Solithromycin, a novel macrolide antibiotic with both intravenous and oral form

62 Azithromycin, a macrolide antibiotic with immunomodulatory effects, is u

63 , led to the discovery of gladiolin, a novel macrolide antibiotic with potent activity against Mycoba

64 ermination of azithromycin, a broad-spectrum macrolide antibiotic, from various biological samples (u

65 e novel form of proarrhythmia seen with this macrolide antibiotic.

66 lipidemic medications (OR = 0.39, P = .004), macrolide antibiotics (OR = 0.40, P = .03), and calcium

67 provides a platform for the discovery of new macrolide antibiotics and may also serve as the basis fo

68 atal cases were less likely to have received macrolide antibiotics and more likely to have received s

69 one-year study on the occurrence and fate of macrolide antibiotics and their metabolites, synthesis b

70 resent a practical, fully synthetic route to macrolide antibiotics by the convergent assembly of simp

71 nd, randomised, placebo-controlled trials of macrolide antibiotics in adult patients with bronchiecta

72 cts, and TPs for the overall mass balance of macrolide antibiotics in urban wastewater systems.

73 Resistance to macrolide antibiotics is a global concern in the treatme

74 Associations between macrolide antibiotics prescribing during pregnancy and a

75 Macrolide antibiotics reduced the frequency of exacerbat

76 uvenimicin, M-4365, and rosamicin classes of macrolide antibiotics via late-stage diversification.

77 Macrolide antibiotics, exemplified by erythromycin, bind

78 induced lethality and identified a series of macrolide antibiotics, including roxithromycin, that pot

79 Macrolide antibiotics, such as erythromycin and josamyci

80 and actively extrudes substrates, including macrolide antibiotics, virulence factors, peptides and c

81 xposure has ceased.High or multiple doses of macrolide antibiotics, when given early in life, can per

82 ion experiment over 25 days except for three macrolide antibiotics, which reached saturation at 300 n

83 patient group with common coprescription of macrolide antibiotics.Conclusions: This pilot study supp

84 nd their sexual partner(s) is complicated as macrolide antimicrobial resistance is now common in many

85 practice of prophylactic administration of a macrolide antimicrobial with rifampin (MaR) to apparentl

86 Macrolides are among the most widely prescribed antibiot

87 ides might be considered in patients in whom macrolides are not indicated according to the current gu

88 ften in combination with a second-generation macrolide, are being widely used for treatment of COVID-

89 dies assessing the efficacy of nonantibiotic macrolides as a long-term therapy for patients with pers

90 The polyhydroxylated 18-membered lichen macrolide (+)-aspicilin was synthesized in 12 steps and

91 nent individual constituents were the parent macrolides azithromycin and clarithromycin.

92 of a beta-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the

93 ely 6 muM] properties of 16-membered lactone macrolides based on spiramycin's aglycone.

94 that TylHI strictly prefers 16-membered ring macrolides bearing the deoxyamino sugar mycaminose.

95 patient data (IPD) meta-analysis to explore macrolide benefit in subpopulations, including those in

96 While bacteriostatic and bactericidal macrolides bind in the nascent peptide exit tunnel of th

97 Rosamicin binds the erythromycin macrolide binding site approximately 60 angstrom from th

98 lts and demonstrate that RplD G70D and other macrolide binding site mutations are prevalent (present

99 ther, TylP is closer in structural design to macrolide-binding TetRs found in pathogens.

100 A "core" airway resistome dominated by macrolide but with high prevalence of beta-lactam, fluor

101 The marine macrolide chagosensine is supposedly distinguished by a

102 tics are bacteriostatic, some members of the macrolide class demonstrate considerable bactericidal ac

103 icient (14 % overall yield) synthesis of the macrolide (-)-clavosolide A.

104 am monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566), with an absolut

105 beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy among a cohort of children

106 beta-Lactam monotherapy and beta-lactam plus macrolide combination therapy are both common empirical

107 Empirical macrolide combination therapy conferred no benefit over

108 questions about the routine empirical use of macrolide combination therapy in this population.

109 iotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoroquinolone monothe

110 1188 to 24,780) found that beta-lactam plus macrolide combination therapy was associated with relati

111 s) with beta-lactam monotherapy, beta-lactam-macrolide combination therapy, or fluoroquinolone monoth

112 beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an absolute differen

113 py and 399 (28.1%) received beta-lactam plus macrolide combination therapy.

114 beta-lactam monotherapy or beta-lactam plus macrolide combination therapy.

115 on hospital day 7 favoring beta-lactam plus macrolide combination therapy.

116 ry-level cephalosporin, fluoroquinolone, and macrolide consumption (standard doses/1000 population/ye

117 Synthesis of the 14-membered macrolide core of migrastatin is accomplished by the use

118 The sluggish dissociation of bactericidal macrolides correlates with the presence in their structu

119 ur results indicate that a single early-life macrolide course can alter the microbiota and modulate h

120 Here, Ruiz et al. show that even a single macrolide course, given early in life, leads to long-las

121 motilin receptor agonist, and by synthesized macrolide derivatives lacking antibiotic or motilide act

122 Complex characterization of macrolide-derived compounds enabled decoupling of indust

123 Macrolide-derived selective KCNJ5MUT inhibitors thus hav

124 omycin (1), a third-generation semisynthetic macrolide discovered by combinatorial copper-catalyzed c

125 lopment of new cephalosporin, quinolone, and macrolide drugs and reduced participation from large pha

126 Macrolide efflux encoded by mef(E)/mel and ribosomal met

127 by the bacterium Streptomyces CBR38; and the macrolides elaiophylin, efomycin A and efomycin G, produ

128 chloroquine or chloroquine with or without a macrolide for treatment of COVID-19.

129 s the slow dissociation rate of the extended macrolides from the ribosome, and increases their bacter

130 r E. coli 70S ribosomes or 50S subunits with macrolide-functionalized azide 2 and 3-ethynylaniline (3

131 More recently, some macrolides have been shown to also possess anti-inflamma

132 roups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroqui

133 rmacological target of tacrolimus (FK506), a macrolide immunosuppressant with several clinical uses,

134 t isolates, and they were not susceptible to macrolides in 25% of patients of both arms.

135 ome efficacious against strains resistant to macrolides in current use.

136 ed selvamicin, an unusual antifungal polyene macrolide, in bacterial isolates from two neighboring an

137 stance, particularly to fluoroquinolones and macrolides, in the major foodborne pathogen Campylobacte

138 the drug binding site can protect cells from macrolide-induced killing, even with inhibitor concentra

139 nd binding properties of chemically distinct macrolide inhibitors of translation, we have identified

140 ia coli ribosome, the extended side chain of macrolides interacts with 23S ribosomal RNA (rRNA) nucle

141 dynamic studies suggested that TylP binds a macrolide intermediate in the tylosin pathway.

142 astereomers of gliomasolide E, a 14-membered macrolides isolated from the marine sponge Phakellia fus

143 ng and securing regulatory approval of a new macrolide/ketolide that is active against macrolide-resi

144 spective describes that structurally similar macrolides/ketolides have clearly mechanistically distin

145 report an unusual mechanism of resistance to macrolide-lincosamide antibiotics mediated by mycobacter

146 megmatis, results in hypersensitivity to the macrolide-lincosamide class of antibiotics.

147 Together, our results suggest a mechanism of macrolide-lincosamide resistance in which the mycobacter

148 berculosis and M. ulcerans, M. tuberculosis (macrolide-lincosamide-streptogramin resistance protein,

149 Tetracycline, multidrug, macrolide-lincosamide-streptogramin, bacitracin, vancomy

150 to resistance mechanisms for tetracyclines, macrolides-lincosamides, sulfonamides, aminoglycosides,

151 erium acnes strains are resistant to topical macrolides, making them less effective.

152 tal synthesis of the highly cytotoxic marine macrolide (-)-mandelalide A (1).

153 This finding suggests that macrolides might be considered in patients in whom macro

154 with CABP, showing the potential to restore macrolide monotherapy for this indication.

155 larly selectively inhibited by idremcinal, a macrolide motilin receptor agonist, and by synthesized m

156 disease, Buruli ulcer, produces a cytotoxic macrolide, mycolactone, whose function(s) in the environ

157 ete the scalable construction of a series of macrolide natural products in as few as 15 linear steps

158 olate reductase inhibitors, fluroquinolones, macrolides, nitrofurans, penicillins, quinolones, sulfam

159 sure to antibiotics (beta-lactam, imidazole, macrolide, nitrofurantoin, quinolone, sulphonamide and t

160 ne or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19.

161 th resistance to beta-lactam antimicrobials, macrolides, or fluoroquinolones.

162 susceptible R. equi isolate outcompeted the macrolide- or rifampin-resistant strains.

163 The MORDOR I trial (Macrolides Oraux pour Reduire les Deces avec un Oeil sur

164 The Macrolides Oraux pour Reduire les Deces avec un Oeil sur

165 stereoselective total synthesis of cytotoxic macrolides pestalotioprolides G and H has been developed

166 considered included limiting indications for macrolide prescriptions, introduction of alcohol-based h

167 ith MRMp were more likely to have received a macrolide prior to presentation, and their treatment was

168 colactone, a cytotoxic and immunosuppressive macrolide produced by Mycobacterium ulcerans, is the cen

169 Macrolide prophylaxis has proved effective in patients w

170 treptomyces venezuelae, represent minimalist macrolide protein synthesis inhibitors.

171 No mutations for macrolide/quinolone resistance was detected.

172 Macrolides, quinolones, doxycycline, nonaromatic antiepi

173 ORC2 kinase activity is not inhibited by the macrolide rapamycin.

174 Mycolactone, an immunosuppressive macrolide released by the human pathogen Mycobacterium u

175 es with mutations previously associated with macrolide resistance (rrl 2058/2059).

176 Macrolide resistance after azithromycin distribution was

177 The occurrence of emm12 strains with macrolide resistance and decreased beta-lactam susceptib

178 The high prevalence of macrolide resistance and long duration of infection afte

179 thromycin (1.5g over 5 days) on selection of macrolide resistance and microbiological cure in men wit

180 . pneumoniae were associated with changes in macrolide resistance and the molecular basis over time i

181 cin as first-line treatment, rapid spread of macrolide resistance as well as emergence of quinolone r

182 clonal expansion of progenitor strains, with macrolide resistance being conferred predominantly by in

183 n, was developed because of rising bacterial macrolide resistance but was withdrawn postapproval afte

184 f antimicrobial resistance revealed multiple macrolide resistance determinants including a novel ribo

185 f antimicrobial resistance revealed multiple macrolide resistance determinants including a novel ribo

186 by acquisition of a cell-surface protein and macrolide resistance determinants via incorporation of a

187 rrent syphilis epidemic by demonstrating how macrolide resistance evolves in Treponema subspecies and

188 Resistome analysis showed an increase in macrolide resistance gene expression in gut microbiota i

189 omal (rplD, rplV and 23S rRNA) mutations, 10 macrolide resistance genes (MRGs) and efflux pump overex

190 9 antibiotic resistance genes detected, five macrolide resistance genes and two tetracycline resistan

191 The Resistance Plus MP assay detected macrolide resistance in 27/33 specimens, resulting in a

192 t azithromycin does not drive acquisition of macrolide resistance in Ct.

193 Macrolide resistance in Mycoplasma genitalium (MG) excee

194 al methylation encoded by erm(B) confer most macrolide resistance in Streptococcus pneumoniae.

195 es are key potential microbial reservoirs of macrolide resistance including the ermX, ermF, and msrD

196 Macrolide resistance increased, reflecting previous stud

197 and posttreatment samples were assessed for macrolide resistance mutations (MRMs) by high-resolution

198 Pre- and post-treatment macrolide resistance mutations were detected by sequenci

199 Selection of macrolide resistance occurred in only 2 of 76 (2.6% [95%

200 The macrolide resistance rate in P1 subtype 1 (P1-1) samples

201 sequence for known polymorphisms conferring macrolide resistance revealed that all 141 tested to pos

202 nticipate this as a generalized mechanism of macrolide resistance used by several bacteria.

203 De novo macrolide resistance was detected in 4.6% of cases.

204 Macrolide resistance was found in 4% (6/169) isolates.

205 Genetic determinants of macrolide resistance were evaluated using established te

206 Determinants of macrolide resistance were higher in the azithromycin gro

207 We correlate the appearance of genotypic macrolide resistance with multiple independently evolved

208 The model included parameters for macrolide resistance, adverse events, hospitalization, a

209 E-emm12, encoding genes for tetracycline and macrolide resistance, and prophage PhiHKU.vir, encoding

210 Of note, in addition to macrolide resistance, virtually all emm12 isolates had a

211 tion and treatment of trachoma that assessed macrolide resistance, without restrictions to the type o

212 23S ribosomal ribonucleic acid (rRNA) loci (macrolide resistance-associated mutations [MRMs]) and in

213 Sixty-two percent of MG-positive men had macrolide resistance-mediating mutations (MRMM) at enrol

214 ection of 23S rRNA mutations known to confer macrolide resistance.

215 imeric constructs are competent in imparting macrolide resistance.

216 of infections, with infrequent selection of macrolide resistance.

217 importantly did not reduce the selection of macrolide resistance.

218 ce our understanding of the genetic basis of macrolide resistance.

219 Saharan Africa but at the cost of amplifying macrolide resistance.

220 subtypes and P1-2 variant types but not with macrolide resistance.

221 f doxycycline-2.5 g azithromycin and de novo macrolide resistance.

222 sed with presumed diminished efficacy due to macrolide resistance.

223 robial therapy for M. genitalium guided by a macrolide-resistance assay.

224 The primary outcome was the ratio of macrolide-resistance determinants in the azithromycin gr

225 eated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days bu

226 Macrolide-resistance in Mycoplasma genitalium (MG) excee

227 There was no evidence of macrolide-resistance in this population.

228 Cases were tested for M. genitalium and macrolide-resistance mutations (MRMs) by polymerase chai

229 De novo macrolide-resistance was detected in 4.6% of cases.

230 ine-2.5g azithromycin and subsequent de novo macrolide-resistance.

231 in or 2.5g-azithromycin cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections

232 n or 2.5 g azithromycin cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections

233 xifloxacin failure were present in 15-22% of macrolide-resistant cases at baseline.

234 ParC mutations were present in 22% of macrolide-resistant cases.

235 genome sequencing of all 1,575 available GAS macrolide-resistant clinical isolates of all infection t

236 ant isolate in 1998, three epidemic waves of macrolide-resistant GAS infections have occurred, with p

237 at each of the three large epidemic peaks of macrolide-resistant GAS infections occurring in Iceland

238 onths, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treatment arm, but n

239 cal conjugate vaccine (PCV7) in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IP

240 Following PCV13 introduction, dual macrolide-resistant IPD decreased 74.1% (incidence 0.32/

241 In Iceland, since the detection of the first macrolide-resistant isolate in 1998, three epidemic wave

242 eric mobile genetic elements in 99.3% of the macrolide-resistant isolates of these emm types.

243 Macrolide-resistant M. pneumoniae (MRMp) was detected in

244 At 0.1 microg/ml erythromycin, macrolide-resistant mutants were induced in one Campylob

245 ampylobacter and four Enterococcus) obtained macrolide-resistant mutants, including two strains from

246 are sparse data to indicate the extent that macrolide-resistant Mycoplasma pneumoniae (MRMp) occurs

247 limited treatment options for patients with macrolide-resistant or refractory disease.

248 ew macrolide/ketolide that is active against macrolide-resistant pathogenic bacteria.

249 The macrolide-resistant phenotype was found in 50.8% of fema

250 as a transient increase in the proportion of macrolide-resistant S. aureus strains following azithrom

251 However, other macrolide-resistant serotypes (eg, 15A and 35B) not curr

252 In equine macrophages, the macrolide-resistant strain did not increase in bacterial

253 is not likely to achieve cure rates >80% in macrolide-resistant strains, in a similar range as recen

254 enomic analysis of the airway reveals a core macrolide resistome harbored by the host microbiome.

255 ss of R. equi strains that were resistant to macrolides, rifampin, or both, resulting in impaired in

256 ho are treated is a 3-drug regimen including macrolide, rifamycin, and ethambutol that is continued f

257 an everninomicin fragment conjugated to the macrolide rosamicin via a rare nitrone moiety.

258 Syntheses of two 14-membered macrolides Sch-725674 and Gliomasolide C are described h

259 proportion of wild-type 23 S rRNA (presumed macrolide sensitive) infections cured after 1.5g and azi

260 Further exploration of macrolides showed that KCNJ5MUT was similarly selectivel

261 Finally, polyketide-based macrolides similar to peloruside A and a hydroxy sphingo

262 s the key structural element determining the macrolides' slow dissociation from the ribosome and like

263 ygenation and acetylation pattern as well as macrolide structure, e.g., monocyclic nonanolide core or

264 molecular descriptors to better characterize macrolide structures.

265 Macrolide susceptibility was assessed by genotyping isol

266 ution in erm(41), previously associated with macrolide susceptibility, was identified in 62 isolates

267 sted to possess the genotype associated with macrolide susceptibility.

268 isolates renders these species intrinsically macrolide susceptible.

269 Macrolide-susceptible cases received 2.5 g azithromycin

270 Macrolide-susceptible cases then received 2.5g azithromy

271 cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections, respectively.

272 cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections, respectively.

273 ed in only 2 of 76 (2.6% [95% CI, .3%-9.2%]) macrolide-susceptible infections.

274 (35.7%), while variant 2c was most common in macrolide-susceptible M. pneumoniae (67.5%).

275 MICs for macrolide-susceptible M. pneumoniae (MSMp) were <=0.008

276 tification of a new chimeric swinholide-like macrolide, symplocolide A, as well as the annotation of

277 from participants of the AMAZES (Asthma and Macrolides: The Azithromycin Efficacy and Safety) trial:

278 in subpopulations, including those in which macrolide therapy is not currently recommended.

279 sed controlled trials suggest that long-term macrolide treatment can prevent exacerbations in adult p

280 ronchiectasis guidelines recommend long-term macrolide treatment for patients with three or more exac

281 We also found that macrolide treatment improved the time to first exacerbat

282 However, downsides of long-term macrolide treatment must also be taken into account.

283 Long-term macrolide treatment significantly reduces the frequency

284 Prevention is based on prophylactic macrolide treatment, immunization starting at 6 weeks of

285 wever, owing to the pleotropic properties of macrolides, unintended bacteriological consequences such

286 an ecological study of seasonal patterns in macrolide use and azithromycin resistance in N. gonorrho

287 The selective pressures of widespread macrolide use and PCV7 and PCV13 introductions on S. pne

288 N. gonorrhoeae, finding that population-wide macrolide use is associated with increased azithromycin

289 ntibiotics (cephalosporins, penicillins, and macrolides) used between age 3 months and age 4 years we

290 o received other regimens (cephalosporin and macrolide vs neither drug class).

291 Macrolides were not associated with a significant improv

292 Unlike other macrolides, which carry several side chains, a single de

293 studies with archazolids, complex polyketide macrolides, which present the most potent V-ATPase inhib

294 Rapamycin is a naturally occurring macrolide whose target is at the core of nutrient and st

295 ung, and Blood Institute guideline-adherent (macrolide with parenteral cephalosporin) vs non-guidelin

296 ng, include diverse natural products such as macrolides with potent bioactivities (e.g. antibiotics)

297 with d-desosamine, a quick entry to chimeric macrolides with potential antibiotic activity.

298 Cross-reactivity studies from other macrolides with similar structure were tested.

299 safety of solithromycin, a fourth generation macrolide, with ceftriaxone plus azithromycin for the tr

300 fficacy and safety of solithromycin, a novel macrolide, with moxifloxacin for treatment of CABP.